MedPath

Coffee-bioavailability-cardiovascular health

Not Applicable
Conditions
Oxidative stress, inflammation, endothelial function, blood pressure and lipid profile
Registration Number
RPCEC00000168
Lead Sponsor
(Vidarium) Vidarium, research center on nutrition health and wellness
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
75
Inclusion Criteria

1. Aged = 18 and = 60 years
2. Body mass index (BMI) between 18.8 kg/m2 and 30 kg/m2 up.
3. Habitual coffee drinkers: consumption in the last year of three or more cups / day.
4. No smokers.
5. No highly competitive sportspeople (subjects with a sedentary physical activity, mild or moderate will be included, in no case exceeding 10 hours per week of training).
6. No history and / or diagnosis of chronic diseases (heart attack, hypertension, congestive heart failure, stroke, arrhythmia, dyslipidemia, diabetes mellitus, cancer, chronic renal failure, hepatic dysfunction, hypothyroidism, insomnia, duodenal ulcer, gastritis, malabsorption syndrome, dysautonomia, sleep disturbances and psychiatric disorders).
7. No consumption of drugs: Hypolipidemic agent, antioxidant supplements, anticonvulsants, anti-inflammatories, steroids, psychiatric drugs, hormone replacement therapy.
8. With a maximum of 10 alcohol drinks per week for women and 15 for men.
9. Having a work schedule between 7.00 am and 6.00 pm Monday to Friday and not have to leave the institution during the study.

Exclusion Criteria

1. Women who are pregnant or breastfeeding.
2. Vegetarians.
3. Subjects with secondary symptoms to coffee consumption.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Plasma levels of caffeic acid and ferulic acid (quantitative determination in nmol/L by chromatography). Measurement time: at baseline, 1 hour after the first consumption, 8 weeks after the inclusion. <br>Total antioxidant capacity (umol-equ-TROLOX/L plasma values measured by FRAP and TRAP methods). Measurement time: at baseline, 1 hour after the first consumption, 8 weeks after the inclusion. <br>Delay in LDL oxidation ((lipid peroxidation), LDL oxidation Lag time in seconds). Measurement time: at baseline, 8 weeks after the inclusion.<br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath